BioMarin Pharmaceutical | BMRN - Sales Revenues


BioMarin Pharmaceutical reported $776M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Bayer EUR 9.66B 1.08B Sep/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Insmed USD 142M 34.6M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025